For instance, in the phase II trial NCT04195139, newly diagnosed elderly glioma patients received a combination of the PD1 antibody nivolumab and chemotherapeutic temozolomide (TMZ), or TMZ alone. Here, PDCD1 is linked to central nervous system cancer.